Free Trial
OTCMKTS:CYBN

Cybin (CYBN) Stock Price, News & Analysis

Cybin logo
$6.50 -0.12 (-1.81%)
As of 05/2/2025 04:10 PM Eastern

About Cybin Stock (OTCMKTS:CYBN)

Key Stats

Today's Range
$6.46
$6.85
50-Day Range
$5.00
$8.30
52-Week Range
$4.81
$14.44
Volume
172,844 shs
Average Volume
270,969 shs
Market Capitalization
$139.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Receive CYBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter.

CYBN Stock News Headlines

Elon Musk is all in on these robots …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
Cybin price target lowered to $150 from $190 at H.C. Wainwright
Cybin price target lowered to $73 from $86 at Canaccord
Cybin: Paradigm Changing Ambitions
See More Headlines

CYBN Stock Analysis - Frequently Asked Questions

Cybin's stock was trading at $8.82 at the beginning of the year. Since then, CYBN shares have decreased by 26.3% and is now trading at $6.50.
View the best growth stocks for 2025 here
.

Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cybin investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD) and

Company Calendar

Today
5/03/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CYBN
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$680,000.00
Price / Cash Flow
N/A
Book Value
$0.19 per share
Price / Book
34.21

Miscellaneous

Free Float
170,213,000
Market Cap
$139.60 million
Optionable
Not Optionable
Beta
0.60
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (OTCMKTS:CYBN) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners